|
| 34529955 | Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. | Lancet Haematol | 2021 |
| 33357482 | Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. | Lancet Haematology,The | 2021 |
| 32735641 | Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. | Blood | 2020 |
| 31940591 | Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. | Journal for ImmunoTherapy of Cancer | 2020 |
| 30930134 | Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2019 |
| 30610196 | Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. | Blood Cancer Journal | 2019 |
| 31124580 | Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. | British Journal of Haematology | 2019 |
| 29076150 | A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. | British Journal of Haematology | 2018 |
| 29616859 | Expression of functional folate receptors in multiple myeloma. | Leukemia and Lymphoma | 2018 |
| 28735890 | Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2017 |
| 27587788 | A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. | Cancer Epidemiol Biomarkers Prev | 2016 |
| 27009059 | Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. | Blood | 2016 |
| 26331432 | Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. | American Journal of Hematology | 2015 |
| 24904120 | Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. | Blood | 2014 |
| 24149943 | Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. | Cancer Chemotherapy and Pharmacology | 2014 |
| 22291084 | Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. | J Clin Oncol | 2012 |
| 22640031 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. | Br J Haematol | 2012 |
| 21596852 | Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. | Blood | 2011 |
| 21430775 | Initial genome sequencing and analysis of multiple myeloma. | Nature | 2011 |
| 21517811 | Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. | Br J Haematol | 2011 |
| 20496994 | Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. | Leuk Lymphoma | 2010 |
| 20130475 | Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. | Journal of Clinical Rheumatology | 2010 |
| 20118399 | Conflicts of interest, authorship, and disclosures in industry-related scientific publications. | Mayo Clin Proc | 2010 |
| 19883314 | Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. | Leukemia and Lymphoma | 2009 |
| 19373653 | Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. | Leuk Lymphoma | 2009 |
| 18728964 | Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. | Leukemia and Lymphoma | 2008 |
| 17846595 | Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2007 |
| 16400339 | Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. | Bone Marrow Transplant | 2006 |
| 16920562 | Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. | Biol Blood Marrow Transplant | 2006 |
| 16009946 | Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. | J Clin Oncol | 2005 |
| 15543195 | Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. | Bone Marrow Transplant | 2005 |
| 15803001 | A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. | American Journal of Clinical Oncology: Cancer Clinical Trials | 2005 |
| 14716341 | Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. | Bone Marrow Transplantation | 2004 |
| 15349753 | A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. | Cancer Chemother Pharmacol | 2004 |
| 15570084 | Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. | J Clin Oncol | 2004 |
| 14501711 | Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. | Journal of Urology | 2003 |
| 11956260 | Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. | Journal of Clinical Oncology | 2002 |
| 11257677 | Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. | Journal of Urology | 2001 |
| 11360105 | A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. | Bone Marrow Transplantation | 2001 |
| 11019839 | Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue. | Bone Marrow Transplantation | 2000 |
| 12042040 | Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. | Cytotherapy | 2000 |
| 10355661 | Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. | Journal of Clinical Apheresis | 1999 |
| 19746591 | The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product. | Cytotherapy | 1999 |
| 10068059 | Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors. | Cytokines, Cellular and Molecular Therapy | 1998 |
| 9781947 | A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. | Cancer | 1998 |
| 9377071 | Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF). | | 1997 |
| 8817391 | Large-scale selection of CD34+ peripheral blood progenitors and expansion of neutrophil precursors for clinical applications. | | 1996 |
| 8634412 | Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. | Blood | 1996 |
| 7581092 | Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. | Bone Marrow Transplantation | 1995 |
| 8846012 | Clinical use of selected and expanded peripheral blood CD34+ cells: a preliminary report of feasibility and safety. | | 1995 |